(Medical Xpress)—A new startup company called Editas Medicine (with $43 million in funding) is looking to expand on research that has already led to a system called Clustered Regularly Interspaced Short Palindromic Repeats/Cas (the Cas part is the name of a protein that is carried via RNA to the desired location in a DNA base pair) shortened to CRISPR/Cas. Such research, the team believes, will lead to a new type of gene therapy that could perhaps lead to cures for such diseases as Huntington's, sickle-cell anemia or cystic fibrosis.
↧